Startups channel feed

Flag­ship start­up Em­press Ther­a­peu­tics launch­es to search for small mol­e­cule drug leads in mi­cro­bial DNA

Last year
Financing
R&D

Fra­zier and Ala­mar Bio­sciences cre­ate im­mune and can­cer biotech At­tovia with $60M in fund­ing

Last year
Financing

Syn­cona takes write-down on Swan­Bio as biotech halves work­force to fo­cus on one gene ther­a­py

Last year
Financing
Cell/Gene Tx

En­cod­ed Ther­a­peu­tics, a well-fund­ed CNS gene ther­a­py mak­er, lays off 10% of staff 

Last year
People
Cell/Gene Tx

Once promis­ing can­cer ther­a­py start­up On­corus ad­mits de­feat af­ter lay­ing off most of its staff

Last year
Pharma

Xalud Ther­a­peu­tics pri­or­i­tizes gene ther­a­pies, with ALS now the fo­cus and os­teoarthri­tis on part­ner path 

Last year
People
Cell/Gene Tx

Ec­co­gene nabs $25M Se­ries B for GLP-1 and a NASH drug can­di­date, as com­peti­tors lap the Chi­na biotech

Last year
Financing
China

Re­ju­ve­nate Bio shrinks staff, pipeline fo­cus as George Church spin­out eyes 2024 gene ther­a­py IND

Last year
People
Cell/Gene Tx

Ex-Night­star, Gy­ro­scope and AGTC teams try again for next reti­nal gene ther­a­py with $120M for Bea­con Ther­a­peu­tics

Last year
Financing
Cell/Gene Tx

Lyn­dra Ther­a­peu­tics eyes $180M Se­ries D for po­ten­tial 2026 launch of once-week­ly schiz­o­phre­nia med

Last year
Financing
R&D

Up­stream Bio match­es first fund­ing round with an­oth­er $200M to get asth­ma drug to PhI­II

Last year
Financing

Bit­ter­root Bio nabs $145M Se­ries A with a plan to tack­le chal­leng­ing can­cer tar­get for heart med­i­cines

Last year
Financing

Ace­po­di­a's off-the-shelf cell ther­a­pies get an­oth­er $100M for on­col­o­gy tri­als

Last year
Financing
Cell/Gene Tx

Ex­clu­sive: With $8M, neu­ro start­up Mod­u­lo Bio emerges to test small mol­e­cules for ALS, de­men­tia in CEO’s per­son­al mis­sion

2 years ago
Financing
AI

Ex-Turn­ing Point ex­ecs plan to have their next bet, Aven­zo, on the Nas­daq next sum­mer

3 years ago
Financing

Car­mot rais­es an­oth­er $150M for obe­si­ty drugs, though race by com­peti­tors is well un­der­way

3 years ago
Financing
R&D

Lark­spur Bio­sciences kicks off with $30M+, hunt­ing for new on­col­o­gy im­munother­a­pies

3 years ago
Financing

In wake of Ru­bius down­fall, a new biotech spin­out launch­es to 'take the next step' in red blood cell ther­a­pies

3 years ago
Cell/Gene Tx

Chas­ing the KRAS field, Quan­ta Ther­a­peu­tics bags $50M for two 2024 clin­i­cal tri­als

3 years ago
Financing

Co­manche lines up tri­al for preeclamp­sia siR­NA with Mod­er­na, Med­i­cines Com­pa­ny vets and GV back­ing

3 years ago
Financing
R&D

Short­ly af­ter Clay Sie­gall’s ar­rival, Philip Low’s Mor­phim­mune nabs funds for twist on can­cer ther­a­pies

3 years ago
Financing

SPAC for 2025 BLA: Non-vi­ral gene ther­a­py biotech en­Gene, steered by ex-Myth­ic lead­ers, finds For­bion blank check

3 years ago
Deals
Cell/Gene Tx

Lil­ly’s Pre­vail taps Jen­nifer Doud­na's spin­out Scribe Ther­a­peu­tics for neu­ro ge­net­ic med­i­cines

3 years ago
Deals
Cell/Gene Tx

On a per­son­al mis­sion for his daugh­ter, Paul Bres­ge launch­es an­oth­er eye dis­ease biotech with $100M for Ray Ther­a­peu­tics

3 years ago
Financing
Cell/Gene Tx
First page Previous page 28293031323334 Next page Last page
A service from the Financial Times